MM120 · program

Lysergide D-tartrate (MM120 / LSD) for Post-traumatic stress disorder

Phase 3ActiveDefinium Therapeutics, Inc. (DFTX)

Indications for MM120: Generalized anxiety disorder · Phase 3 Major depressive disorder · Phase 3 Post-traumatic stress disorder · Phase 3 Attention-deficit/hyperactivity disorder · Discontinued

DT120 ODT (formerly MM120; lysergide D-tartrate / LSD) for posttraumatic stress disorder (PTSD) - the third indication after the lead GAD program (Voyage/Panorama) and MDD (Emerge/Ascend). Announced at Definium Therapeutics' April 22, 2026 Investor & Analyst Day as a planned Phase 3 study named 'Haven': ~200 participants randomized 1:1 to a single dose of DT120 ODT vs placebo, primary endpoint change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) at Week 8, study initiation expected in 2027. Not yet registered on ClinicalTrials.gov.

Data current as of

Development timeline

Phase 3Aug 2023 – Jan 2027
  1. UpcomingPhase 3 Haven study of DT120 ODT in PTSD expected to initiate in 2027↗
  2. FinancingDefinium Therapeutics closes upsized $805M public equity offering (~$758M net) funding DT120 program↗
  3. Definium Therapeutics announced expansion of the DT120 ODT program into PTSD with the planned Phase 3 'Haven' study (~200 participants, 1:1 DT120 ODT vs placebo, primary endpoint CAPS-5 at Week 8), initiation expected in 2027. No NCT registered as of this record.↗
  4. Corporate rebrand / name changeMind Medicine (MindMed) rebrands as Definium Therapeutics↗
  5. Licensing dealCatalent grants MindMed exclusive license to Zydis ODT technology for MM-120 (lysergide)↗

Readouts

  • 2027AnticipatedRegistry results

    Phase 3 Haven study of DT120 ODT in PTSD expected to initiate in 2027 ↗

Mechanism of action (compound-wide)

LSD acts across serotonin receptor subtypes; the company describes MM120 as a 5-HT2A partial agonist (IUPHAR classifies LSD as a full 5-HT2A agonist). Antidepressant effects attributed primarily to 5-HT2A agonism.

TargetActionAffinity
5-HT2AprimaryHTR2APartial agonistpKi 9.4ⓘ
5-HT1AHTR1AAgonistpKi 9ⓘ
5-HT2CHTR2CAgonistpKi 8.2ⓘ

← Full MM120 compound page (identity, identifiers, all indications)

Sources

  1. Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day (Apr 22, 2026) — Definium Therapeutics, Inc.
  2. Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares — Definium Therapeutics, Inc.
  3. Lysergide (LSD), Ligand 17 — IUPHAR/BPS
  4. MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis Fast-Dissolve Technology for Use with MM-120 — MindMed / Definium Therapeutics
  5. MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 — Definium Therapeutics